Route of progesterone administration for luteal phase support may affect outcome of controlled ovarian hyperstimulation for IVF with ICSI using GnRH antagonist

• Published in: Journal of assisted reproduction and genetics Vol. 25; no. 9-10; pp. 499 - 502
• Main Authors: Bahceci, Mustafa, Ulug, Ulun
• Format: Journal Article
• Language: English
• Published: Boston Springer US 01.09.2008; Springer Nature B.V
• Subjects: Adult; Clinical outcomes; Female; Fertilization in Vitro - methods; Gonadotropin-Releasing Hormone - agonists; Gonadotropin-Releasing Hormone - antagonists & inhibitors; Gonadotropin-Releasing Hormone - metabolism; Gynecology; Human Genetics; Humans; Luteal Phase - drug effects; Medicine; Medicine & Public Health; Ovarian Hyperstimulation Syndrome - drug therapy; Ovaries; Ovulation Induction; Pregnancy; Pregnancy complications; Progesterone - administration & dosage; Progesterone - therapeutic use; Reproductive Medicine; Retrospective Studies; Short Communication; Sperm Injections, Intracytoplasmic; Vagina; Womens health; Istanbul Turkey; Switzerland; Turkey; IVF; Progesterone; Intramuscular; Vaginal
• ISSN: 1058-0468; 1573-7330
• DOI: 10.1007/s10815-008-9269-3

Purpose This study evaluated the impact of route of progesterone administration as luteal phase support on the outcome of assisted conception cycles. Methods Intramuscular progesterone in oil (IMP) at 100 mg daily was administered to 903 women following oocyte retrieval whereas vaginal progesterone gel (VMP) at 90 mg was administered twice daily to 1,110 women. Retrospective analysis was performed according to the type of GnRH analogue used. Implantation (IR), clinical pregnancy (CPR) and biochemical pregnancy rates (BPR) were main outcomes. Results In GnRH agonist cycles, neither IR, CPR or BPR differed according to the route of progesterone. However, in GnRH antagonist cycles, IR and CPR were significantly lower in VMP group compared to IMP group. BPR also was significantly higher in VMP group compared to IMP group. Conclusion Our results suggest that route of progesterone administration for luteal phase support can be an important prognostic factor according to the type of GnRH analogue used for controlled ovarian hyperstimulation.